1. Partners for Measles Advocacy—7th Annual Meeting
27-28 Feb 2007

2. Meeting Objectives
To report on progress of Yr 6 and Yr 7 priority activities
To explore additional integration of health initiatives, particularly malaria prevention
To report on and discuss resource mobilization and communication activities

3. Introduction-”What is past is prologue”
Achievements:
60% reduction in measles mortality
2.3 m deaths averted
>360m children vaccinated
MCV1 54%-65%
Lessons learned
Importance of partnership
Integration
Mobilization/awareness/advocacy
Challenges
Sustain the gains
Pakistan and India
$$$$$

4. Measles Control Goals by WHO Region
Americas, Europe, E. Mediterranean, W. Pacific have elimination goals
GIVS Goal:
90% reduction in deaths
by 2010 (vs. 2000)
2010
2010
2012
This map shows the 192 member countries of WHO grouped into 6 regions with their respective measles control goals. 4 Regions (Americas, Europe, E. Mediterranean and W. Pacific) have measles elimination goals with target dates as shown and 2 regions (Africa and SE Asia) have measles mortality reduction goals. The overriding global goal established by the World Health Assembly is to reduce measles deaths by half by 2005.
2000
Africa and SE Asia have
mortality reduction goals

5. Reaching Measles Goal 2010-Can we get there?
Epidemiology/program
Major gains but challenges to sustain (e.g followup)
Global goal but regional variation
MCV1 improving but far from adequate
SIA integration ongoing but challenges
Surveillance priority but different indicators
Partnership
Need to include civil society
Need $479m (gap: $281m)
Supply
Challenges to vaccine security

6. Tackling Big Challenges
Pakistan and India
Challenges: low MCV1, huge target pop, surveillance, competing priorities, ?resistance
Progress: commitment to EPI and measles—SIAs, TAG—next steps?
Global vs. National priorities/timelines?
Strengthening routine EPI-AFR,EMR
Progress: different stages but w/ general reliance on RED
Challenge: intra-national variation, expanding >80%, importance of key national managers

7. Challenges, con’t Discussion: routine--SIA
Need for a diagonal approach to reach common target of reducing morbidity and mortality
Utilization of polio infrastructure can be essential for both surveillance and implementation
Opportunities for advocacy--Challenge to identify discrete targeted indicators

8. Expanding the Benefits through Integration
Progress: M&M
Steady increase in ITN distribution (30m) w/ extraordinary results (e.g. SL)
Lessons learned
Role of leadership and partnerships
Importance of community (“public”) participation—developing “net culture”
Challenges
Operational issues—logistics, options, safety, $
Measurement of impact—
ITN distribution in Togo, Niger, Mozambique
Sustainable decentralized, integrated system
Sustaining gains and breakthrough?

9. Integration, con’t Discussion Dialectic between routine—SIA?
Further need to measure impact-- disease? Interaction w/ EPI program?
Working groups—practical next steps
Operational research
GFATM—develop standard proposal?
Communication

10. Outbreaks, Emergencies, SIA
Importance of data: surveillance to detect outbreaks, outbreak case data, link to EPI program data
Data can give false sense of security
Emergencies give visibility—advocacy?
M&M SIA quality
Need sufficient preparation time and data driven plans
Importance of M&E—review linkages?
EPI platform requires further training, staff, ops $, and support
Importance of partnerships—public health approach
Need for new specific M&M SIA guidelines?

11. Final summary 2005 goal: “We did it”
2010 goal: “We are better educated as to challenge and how to get there”
“When the nose of the camel goes into tent you get the whole camel”
Future: “We have a moral imperative to work together”